The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2022 | Consolidation therapy and updated results from the EMN02 trial
In this video, Pieter Sonneveld, MD, PhD, Erasmus Medical Center Cancer Institute, Rotterdam, The Netherlands, shares some updates from the EMN02 trial (NCT01208766), highlighting the importance of consolidation therapy in patients with newly diagnosed multiple myeloma, and the need to make consolidation therapy a standard part of clinical practice. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.
